Multidisciplinary weight-loss program
Multidisciplinary weight-loss program has been studied in 2 papers since 2024: 2 trials in people. The newest paper, Sep 4, 2024: “Muscle Strength and Phase Angle Are Potential Markers for the Efficacy of Multidisciplinary Weight-Loss Program in Patients with Sarcopenic Obesity”.
2 papers study it6 findingsUpdated
See all 2 papers on multidisciplinary weight-loss program
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries.
“When implementing the model by including the dichotomous variable SMMI delta changes instead of the variable HGS, we found that the interaction was not statistically significant (p-value = 0.2563).”
None of its findings points the other way.
- 2 independent labs in 2 countries
- Funder: Italian Government Ministry of Health
- Human trial2
Studies in people
2 studies gave multidisciplinary weight-loss program to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of sarcopenic obesity42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic no change: Has no effect on muscle mass | Trial4 weeks | 2,004 people62% female patientsmean age of 56 (±14) yearsPatients admitted for diagnostic evaluation and a 4-week multidisciplinary rehabilitation program aimed at addressing obesity | Journal of clinical medicine, Sep 4, 2024 |
down: Decreases body weightmedian 11.7 kg (range 0-33) up: Increases liver transplant eligibility8 transplanted and 4 waitlisted of 19 patients | Treated cohortAugust 2019 to September 2023 | 19 people18 years or olderHigh BMI liver transplant candidates | Transplantation, May 17, 2024 |
What did studies of multidisciplinary weight-loss program find?
4Studies of multidisciplinary weight-loss program measured 4 outcomes, among them muscle mass, muscle mass and liver transplant eligibility.
Muscle mass
no changein humans1
1 study
Muscle mass
no changein humans1
Multidisciplinary weight-loss program showed no clear effect on muscle mass in logistic regression model for No SO state.
“When implementing the model by including the dichotomous variable SMMI delta changes instead of the variable HGS, we found that the interaction was not statistically significant (p-value = 0.2563).”
Human trialin logistic regression model for No SO state4 weeks
Journal of clinical medicine
Muscle mass
no changein humans1
1 study
Muscle mass
no changein humans1
Multidisciplinary weight-loss program showed no clear effect on muscle mass in humans (sarcopenic obesity).
“Muscle mass (MM) and SMMI remained unchanged in the studied cohort.”
Human trialsarcopenic obesity4-weekn = 188
Journal of clinical medicine
Liver transplant eligibility
upin humans1
1 study
Liver transplant eligibility
upin humans1
Multidisciplinary weight-loss program is linked with higher liver transplant eligibility in humans (high BMI liver transplant candidates) (8 transplanted and 4 waitlisted of 19 patients).
“Eight patients received a transplant and 4 more patients were waitlisted.”
Humanshigh BMI liver transplant candidatesn = 19
Transplantation
Body weight
downin humans1
1 study
Body weight
downin humans1
Multidisciplinary weight-loss program is linked with lower body weight in humans (high BMI liver transplant candidates) (median 11.7 kg (range 0-33)).
“Median weight loss was 11.7 kg for all 19 patients (range, 0-33).”
Humanshigh BMI liver transplant candidatesn = 19
Transplantation
What is multidisciplinary weight-loss program linked with?
1Studies link multidisciplinary weight-loss program with sarcopenic obesity.
Sarcopenic obesity
downin humans1
1 study
Sarcopenic obesity
downin humans1
Multidisciplinary weight-loss program lowers the risk of sarcopenic obesity in patients with sarcopenic obesity at admission (42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic).
“At the end of the multidisciplinary program, 42.6% (n = 80) out of 188 SO patients at admission resulted in not being sarcopenic (No SO discharge), while for 108 patients, the SO condition was unchanged (SO discharge).”
Human trialin patients with sarcopenic obesity at admission4 weeksn = 188
Journal of clinical medicine
Multidisciplinary weight-loss program lowers the risk of sarcopenic obesity in humans (sarcopenic obesity) (42.55% (80 patients)).
“At discharge, 80 patients (42.55%) were no longer classified as sarcopenic and showed significant improvements in HGS.”
Human trialsarcopenic obesity4-weekn = 188
Journal of clinical medicine